Core Insights - The Hang Seng Index Company announced the inclusion of Baize Medical (02609) in the Hang Seng Composite Index, effective after market close on September 5, 2025, with trading starting on September 8, 2025 [1] - Baize Medical is expected to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Baize Medical plans to hold a board meeting on August 28 to consider and approve its interim results [1] Company Overview - Baize Medical is a major Chinese oncology medical group engaged in investment and provision of medical-related services [2] - The group operates and manages eight hospitals across Beijing, Tianjin, Shanxi, Anhui, and Henan provinces, focusing on providing comprehensive oncology medical services [2] Research and Development - Baize Medical, in collaboration with renowned hospitals, published the "Oncology Rehabilitation Expert Consensus (2025)" in a prestigious academic journal, emphasizing the importance of cancer rehabilitation in improving patient quality of life and reducing treatment side effects [1] - The consensus outlines the target population for cancer rehabilitation, assessment standards, and five key rehabilitation strategies, highlighting the role of multidisciplinary teams (MDT) in the rehabilitation process [1]
佰泽医疗(02609)获纳入恒生综合指数 有望成为港股通标的